体外冲击波治疗间歇性跛行的可行性双盲随机安慰剂对照试验
这项可行性双盲随机安慰剂对照试验将单侧间歇性跛行患者随机分配至体外冲击波治疗(ESWT)组或假治疗组,每周三次、共三周作用于小腿肌肉。主要结局为无痛步行距离(PFWD)和最大步行距离(MWD);结果显示活性治疗组在所有时间点均较假治疗组有统计学显著改善,12周时PFWD改善276%、MWD改善167%,且未发现安全性问题。
要点
- ESWT作用于小腿肌肉安全且耐受良好,未记录到即刻或延迟的不良反应。
- 12周时活性组PFWD改善276%、MWD改善167%,所有时间点均优于假治疗组(P<.05)。
- ESWT作为间歇性跛行的无创替代治疗显示出潜力,但作用机制与疗效持久性待研究。
核心结论
- ESWT应用于小腿时安全且耐受良好,并显著改善步行距离。
- ESWT作为间歇性跛行的替代无创治疗早期结果显示出很大潜力。
- ESWT的作用机制、临床效果持久性和成本效益仍需进一步研究。
研究设计与样本
- 可行性双盲随机安慰剂对照试验,单侧间歇性跛行患者随机接受ESWT或假治疗。
- 治疗作用于小腿肌肉,每周三次、共三周。
- 主要结局为无痛步行距离(PFWD)和最大步行距离(MWD)。
- 次要结局包括安全性与耐受性、运动前后踝肱指数及生活质量(SF-36、EQ-5D-3L、Vascular Quality of Life)。
主要发现
- 活性治疗组在全部时间点的MWD和PFWD较假治疗组均有统计学显著改善(P<.05)。
- 治疗后12周,活性组PFWD改善276%,MWD改善167%。
- 本试验中ESWT未出现即刻或延迟的治疗安全性问题,也未记录到不良效应。
临床怎么用
- 当前间歇性跛行的保守治疗包括监督下运动训练。
- ESWT可作为间歇性跛行的一种替代无创治疗选择,但需进一步研究确认机制与持久性。
局限性
- ESWT的作用机制、临床效果持久性和成本效益尚不明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intermittent claudication is the most common symptom of peripheral arterial disease. Previous research has suggested that extracorporeal shockwave therapy (ESWT) may induce angiogenesis in treated tissue. The objective of this feasibility pilot trial was to assess the safety, tolerability, and efficacy of ESWT as a novel treatment. METHODS: Patients with unilateral claudication were randomized to receive ESWT or sham treatment to the calf muscle three times per week for 3 weeks. Primary outcomes were pain-free walking distance (PFWD) and maximum walking distance (MWD). Secondary outcomes included safety and tolerability of ESWT treatment, ankle-brachial index before and after exercise, and quality of life assessed using generic (36-Item Short Form Health Survey, EuroQol-5 Dimension 3-Level) and disease-specific (Vascular Quality of Life) instruments. Participants were assessed at baseline and 4, 8, and 12 weeks after treatment. Feasibility outcomes included recruitment and attendance rates for treatment and follow-up. RESULTS: Thirty patients were recruited in total. Statistically significant (P < .05) improvements at all time points were observed in the active treatment group for both MWD and PFWD compared with the sham treatment group. PFWD improved by 276% in the active group and MWD improved by 167% in the active group at 12 weeks after treatment. There were no immediate or delayed treatment safety concerns or documented adverse effects of treatment with ESWT in this trial. CONCLUSIONS: ESWT is safe and well tolerated when it is applied to the calf and demonstrated significant improvements in walking distances. Current conservative management of intermittent claudication includes supervised exercise. The early results with ESWT as an alternative, noninvasive treatment option show great potential. The mechanism of action, durability of the clinical effect, and cost-effectiveness of ESWT for claudication require further investigation.
引用
- Harwood AE, Green J, Cayton T, et al. A feasibility double-blind randomized placebo-controlled trial of extracorporeal shockwave therapy as a novel treatment for intermittent claudication. J Vasc Surg. 2017. PMID: 28943002. doi:10.1016/j.jvs.2017.07.105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。